# SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT06649292** · PHASE3 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 524 (estimated)

## Conditions studied

- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SHR-A1904
- **DRUG:** Paclitaxel, Docetaxel, Irinotecan

## Key facts

- **NCT ID:** NCT06649292
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2027-09-20
- **Final completion:** 2028-03-20
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649292, "SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06649292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*